NCT00923442Enrolling by invitation
Biology Studies of Hematologic Cancers
Hematologic Malignancy Biology Study
Source: ClinicalTrials.gov · Last updated 21 Oct 2026
Brief summary (registry, in English)
This study will collect tumor samples from people with cancers of the blood, bone marrow, or lymph glands for laboratory study of the biology of these conditions. Such studies contribute to a better understanding of cancer biology and to the development of new treatments. Planned studies include: * Examination of individual cancer cells and to search for differences compared to other types of cancer and normal cells * Examination of the chromosomes and genes in cancer cells and to search for differences compared to other types of cancer and normal cells * Development of sensitive methods to detect small amounts of cancer that remain after treatment * Search for new cancer proteins that might serve as targets for treatment * Investigation of methods to develop cancer vaccines. Patients from \>= 1 to 75 years of age with acute lymphocytic leukemia, acute myelogenous leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, juvenile myelomonocytic leukemia, non-Hodgkin's lymphoma, Hodgkin's disease, and other hematologic malignancies may be eligible for this study. Blood or bone marrow samples will be collected when sampling is required for the patient's medical care. Cells from some individuals will be grown in test tubes, establishing cell lines or in animals, establishing xenograft models. (A xenograft is transplantation of cells of one species to another species.)
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 550 (estimated)
- First submitted
- 17 Jun 2009
- Start date
- 24 Feb 2004
- Lead sponsor
- National Cancer Institute (NCI)
- Diseases
- Acute lymphoblastic leukaemia, Hodgkin lymphoma, Myelodysplastic syndromes, Acute myeloid leukemia, Childhood cancers
- NCT number
- NCT00923442
What you commit to
- Study type: Observational
- Planned participants: 550
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
Criteria the registry did not label
- INCLUSION CRITERIA
- Confirmed pathological diagnosis of any hematologic malignancy or pre-malignant blood disorder, including but not restricted to the following:
- Acute Lymphocytic Leukemia (ALL)
- Acute Myelogenous Leukemia (AML)
- Myelodysplastic Syndrome (MDS)
- Chronic Myelogenous Leukemia (CML)
- Juvenile Myelomonocytic Leukemia (JMML, J-CML)
- Non-Hodgkin's Lymphoma (NHL)
- Hodgkin's Disease
- Tumor tissue that has been previously collected and is available for study or that can be collected with minimal additional risk to the subject during sampling required for routine patient care.
- Age: \>= 1 years.
- Prior therapy: no restrictions
- Subject, parent/guardian, legally authorized representative (LAR), or durable power of attorney must be able to give informed consent and sign the informed consent document.
Age in the registry: 1 year to 120 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Institutes of Health Clinical Center Coordinator of this site? Confirm its status | Bethesda | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.